Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Case report

A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma

Authors: Tianxiang Cui, Xinwei Diao, Xiewan Chen, Shaojiang Huang, Jianguo Sun

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well. No report involves a side effect of delayed high fever of sorafenib. This manuscript describes a case of EHCC in the thoracic and abdominal cavities, who showed a delayed high fever and maculopapules during sorafenib treatment.

Case presentation

The patient is a 63-year-old Chinese male with advanced EHCC, taking sorafenib 400 mg twice daily. On the tenth day, red maculopapules appeared all over the body. On the same day, the patient began to suffer from continuous high fever. Due to these effects, the patient was asked to cease sorafenib treatment, and the high fever and maculopapules were alleviated quickly. However, the symptoms were present again upon re-challenge of sorafenib. Prednisone was then administered to control the symptoms, with the dosage gradually reduced from 30 to 5 mg/day in 1.5 months. No recurrence of fever or maculopapules has been found. Tumor response reached partial response (PR) and progression free survival (PFS) reached 392 days + by the date of Apr. 14th, 2016.

Conclusion

EHCC could be treated like orthotopic HCC by oral administration of sorafenib, which shows good tumor response and survival benefit. Delayed high fever and maculopapules are potential, rare and severe side effects of sorafenib, and could be effectively controlled by glucocorticoid.
Literature
1.
Yamashita M, Nagamine Y, Ozaki K, Ueshima S, Takahashi H, Inoue H, et al. An autopsy case of a cirrhotic ectopic liver with a review of the literature. Acta Hepatol Jpn. 1985;26:510–4.CrossRef
2.
Pavel Z, Lubomir M, Peter I, Jan F. Ectopic liver: different manifestations, one solution. World J Gastroenterol. 2013;19(38):6485–9.CrossRef
3.
Arakawa M, Kimura Y, Sakata K, Kubo Y, Fukushima T, Okuda K. Propensity of ectopic liver to hepatocarcinogenesis: case reports and a review of the literature. Hepatology. 1999;29(1):57–61.CrossRefPubMed
4.
Watanabe M, Matsura T, Takatori Y, Ueki K, Kobatake T, Hidaka M, et al. Five cases of ectopic liver and a case of accessory lobe of the liver. Endoscopy. 1989;21(1):39–42.CrossRefPubMed
5.
Sato S, Watanabe M, Nagasawa S, Niigaki M, Sakai S, Akagi S. Laparoscopic observations of congenital anomalies of the liver. Gastrointest Endosc. 1998;47(2):136–40.CrossRefPubMed
6.
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172–9.CrossRefPubMed
7.
Caygill CP, Gatenby PA. Ectopic liver and hepatocarcinogenesis. Eur J Gastroenterol Hepatol. 2004;16(8):727–9.CrossRefPubMed
8.
Asselah T, Condat B, Cazals-Hatem D, Hassani Z, Bernuau J, Groussard O, et al. Ectopic hepatocellular carcinoma arising in the left chest wall: a long-term follow-up. Eur J Gastroenterol Hepatol. 2001;13(7):873–5.CrossRefPubMed
9.
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.CrossRefPubMed
10.
Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98(5):326–34.CrossRefPubMed
11.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMed
12.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.CrossRefPubMed
13.
Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9(6):739–45.CrossRefPubMed
14.
Tsuji K, Takemura K, Minami K, Teramoto R, Nakashima K, Yamada S, et al. A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinom. Clin J Gastrornterol. 2013;6(3):255–7.CrossRef
15.
Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SW. Case of sorafenib-induced thyroid storm. J Clin Oncol. 2013;31(16):262–4.CrossRef
16.
Hootegem AV, Verslype C, Van Steenbergen WV. Sorafenib-induced liver failure: a case report and review of the literature. Case Reports Hepatol. 2011;2011:941395.PubMedPubMedCentral
17.
Takeda H, Nishikawa H, Iguchi E, Matsuda F, Kita R, Kimura T, et al. Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases. Clin J Gastroenterol. 2012;5(4):407–12.CrossRefPubMedPubMedCentral
Metadata
Title
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma
Authors
Tianxiang Cui
Xinwei Diao
Xiewan Chen
Shaojiang Huang
Jianguo Sun
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2590-9

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Evaluation of TgH(CX3CR1-EGFP) mice implanted with mCherry-GL261 cells as an in vivo model for morphometrical analysis of glioma-microglia interaction

Research article

COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data

Study protocol

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer

Research article

Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer

Research article

Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy

Research article

Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits